Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease

Serum soluble Fas (sFas) levels are associated with erythropoietin (Epo) hyporesponsiveness in patients with chronic kidney disease (CKD). Whether sFas could predict the need for erythropoiesis-stimulating agent (ESA) usage and its influence in erythropoiesis remain unclear. We evaluated the relatio...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Am J Physiol Renal Physiol
Päätekijät: Chiloff, Daniela Mendes, de Almeida, Danilo Candido, Dalboni, Maria A., Canziani, Maria Eugênia, George, Sunil K., Morsi, Alshaimaa Mahmoud, El-Akabawy, Nadia, Porada, Christopher D., Durao, Marcelino Souza, Zarjou, Abolfazl, Almeida-Porada, Graca, Goes, Miguel Angelo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Physiological Society 2020
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7474254/
https://ncbi.nlm.nih.gov/pubmed/32003597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajprenal.00433.2019
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia